Clinical trials: Primary Mediastinal B-cell Lymphoma
Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL.
- Conditions
- Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle-cell Lymphoma
- Trial name
- NCT02631044
- Testing
- JCAR017 (lisocabtagene maraleucel) single-dose schedule, JCAR017 (lisocabtagene maraleucel) 2-dose schedule
- Where
- 14 sites in United States
- Volunteers
- 387 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma
The goal of this clinical trial is to learn if a new type of chimeric antigen receptor (CAR) T-cell therapy called atlacabtagene autoleucel is effective and safe for the treatment large B-cell lymphomas (LBCL) that have not…
- Conditions
- Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Transformed Non-Hodgkin Lymphoma
- Trial name
- ENABLE-2 (NCT06486051)
- Testing
- Fludarabine, Cyclophosphamide, WZTL-002 CAR T-cells
- Where
- 3 sites in New Zealand
- Volunteers
- 60 people
- Sponsor
- Malaghan Institute of Medical Research
Diffuse Large B Cell Lymphoma (DLBCL)
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
This non-randomized, open label, multi-site, first-in-human, Phase 1/2 study CRC-403 will evaluate the safety and efficacy of bbT369 in subjects with relapsed and/or refractory B cell non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT05169489
- Testing
- bbT369
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Regeneron Pharmaceuticals
Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy
This study evaluates whether tumors present in patients with cancer who are planned to get CAR T-cells have low amounts of oxygen (hypoxia).
- Conditions
- Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Malignant Neoplasm
- Trial name
- NCT04409314
- Testing
- Fluorine F 18-fluoroazomycin Arabinoside, Positron Emission Tomography
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of California, San Francisco
Cardiovascular Diseases, B-cell Acute Lymphoblastic Leukemia
CAR T Cell Therapy Related Cardiovascular Outcomes
This will be a cohort study of all patients receiving Cluster of Differentiation 19 (CD19)-specific CAR T cell therapy for relapsed/refractory B cell haematological malignancies.
- Conditions
- Cardiovascular Diseases, B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
- Trial name
- CARTCO (NCT05130489)
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- University College London Hospitals
Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma
Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity
The purpose of this research is to replace one of participants' outpatient chimeric antigen receptor T-cell (CAR-T) therapy follow up visits with a virtual or "telemedicine" visit.
- Conditions
- Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, High-grade B-cell Lymphoma
- Trial name
- NCT04503538
- Testing
- Telemedicine visit
- Sponsor
- Wake Forest University Health Sciences
Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
This is a Phase 1b/2, open-label, non-randomized multicenter study to assess the safety and efficacy of ibrutinib and lenalidomide in combination with DA-EPOCH-R in subjects with relapsed/refractory Diffuse Large B-cell Lymphoma…
- Trial name
- NCT02142049
- Testing
- Ibrutinib, DA-EPOCH-R, Lenalidomide
- Where
- 10 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pharmacyclics LLC.
Diffuse Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B-cell Lymphoma
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
This is a phase 2 study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (ibrutinib), in combination with bendamustine and rituximab (BR) in subjects with previously treated aggressive B cell non Hodgkin lymphoma (aB-NHL)…
- Conditions
- Diffuse Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B-cell Lymphoma, Transformed Indolent Lymphoma, Recurrent Disease
- Trial name
- NCT02747732
- Testing
- Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6
- Where
- 2 sites in Israel
- Volunteers
- 72 people
- Sponsor
- Meirav Kedmi MD
Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML
This study aims at evaluating the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of a chimeric antigen receptor targeting the B-cell surface antigen CD19…
- Conditions
- Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma
- Trial name
- NCT04787263
- Testing
- CD19-CAR_Lenti T cell
- Where
- Italy
- Volunteers
- 32 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
This phase I/II trial studies the safety of acalabrutinib and axicabtagene ciloleucel in treating patients with B-cell lymphoma. Acalabrutinib may stop the growth of tumor cells by blocking key pathways needed for cell growth.
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Trial name
- NCT04257578
- Testing
- Acalabrutinib, Axicabtagene Ciloleucel
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Washington
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
This phase Ib trial studies the effects of NKTR-255 in combination with chimeric antigen (CAR)-T cell therapy and to see how well they work in treating patients with large B-cell lymphoma that has come back (relapsed) or does not…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma
- Trial name
- NCT05359211
- Testing
- Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Fred Hutchinson Cancer Center
B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
This phase II trial tests the safety, best dose, and effectiveness of epcoritamab when given with etoposide, cyclophosphamide, vincristine, doxorubicin, prednisone and rituximab (EPOCH-R) for the treatment of patients with…
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT07097363
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Washington
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This phase II trial tests how well epcoritamab in combination with rituximab, gemcitabine and oxaliplatin (R-GemOx) works as treatment given after the cancer has not responded to other treatments (salvage therapy) before…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Trial name
- NCT07365306
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- City of Hope Medical Center
Primary Mediastinal B-Cell Lymphoma
A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma
A non-profit study designed with the aim of analysing the phenotype and molecular characteristics (central review) and evaluating prospectively the role of PET-scans in the management of primary mediastinal lymphoma treated with…
- Trial name
- NCT00944567
- Where
- 20 sites in Italy, Spain and 2 more
- Volunteers
- 125 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Primary Mediastinal Large B-cell Lymphoma With CNS Involvement
This is a retrospective, multicenter study focused on patients with a known diagnosis of PMLBCL which experienced a CNS relapse during the course of their disease to obtain information about the clinical characteristics, the…
- Trial name
- NCT06024694
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- IRCCS San Raffaele
Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
This is a Phase I, prospective, dose-finding study to evaluate the safety, persistence, and clinical activity of GF-CART01 in subjects aged 18-70 with relapsed or refractory (R/R) B-cell hematological malignancies and failure of…
- Conditions
- Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory, Follicular Lymphoma ( FL), Primary Mediastinal Large B-Cell Lymphoma-Refractory
- Trial name
- CD20/19 CAR T (NCT06703892)
- Testing
- GF-CART01
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- GenomeFrontier Therapeutics TW Co., Ltd.
Diffuse Low Grade B-Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Italian Observational Study on CAR-T Therapy for Lymphoma
The goal of this observational study on chimeric antigen receptor T-cell therapy is to monitor the feasibility, efficacy, toxicity and biomarkers in a real life setting.
- Conditions
- Diffuse Low Grade B-Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- CART-SIE (NCT06339255)
- Where
- Italy
- Volunteers
- 5,300 people
- Sponsor
- Paolo Corradini
Large B Cell Lymphoma, LBCL
Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy
This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of Prizloncel, an anti-CD19/CD20 chimeric antigen receptor T cells following lymphodepleting chemotherapy in participants with…
- Conditions
- Large B Cell Lymphoma, LBCL, Diffuse Large B Cell Lymphoma (DLBCL), Relapse Diffuse Large B Cell Lymphoma
- Trial name
- NCT07875413
- Testing
- Prizloncabtagene Autoleucel
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- AbelZeta Inc.
Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
This is a multi-center, phase I/II study to determine the safety and efficacy of TC011(CD19 Targeted CAR-T) in adult patients with relapsed or refractory large B-cell non -hodgkin lymphoma.
- Conditions
- Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), High-grade B-cell Lymphoma (HGBL)
- Trial name
- TC011 (NCT07473167)
- Testing
- TC011
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- TICAROS Co., Ltd.
Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients…
- Conditions
- Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT06784167
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- OHSU Knight Cancer Institute